CEBPA and acute myeloid leukemia: Overall, these data show that in human AML, CEBPA N-terminal and biallelic mutations - which result in the expression of p30 – are associated to a reduced expression of inflammatory genes, and this can be partially rescued by re-expression of the p42 wild-type isoform.